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Abstract
Background: Methylation changes are frequent in cancers, but understanding how hyper- and hypomethylated
region changes coordinate, associate with genomic features, and affect gene expression is needed to better
understand their biological significance. The functional significance of hypermethylation is well studied, but that of
hypomethylation remains limited. Here, with paired expression and methylation samples gathered from a patient/
control cohort, we attempt to better characterize the gene expression and methylation changes that take place in
cancer from B cell chronic lymphocyte leukemia (B-CLL) samples.
Results: Across the dataset, we found that consistent differentially hypomethylated regions (C-DMRs) across
samples were relatively few compared to the many poorly consistent hypo- and highly conserved hyper-DMRs.
However, genes in the hypo-C-DMRs tended to be associated with functions antagonistic to those in the hyper-
C-DMRs, like differentiation, cell-cycle regulation and proliferation, suggesting coordinated regulation of methylation
changes. Hypo-C-DMRs in B-CLL were found enriched in key signaling pathways like B cell receptor and p53
pathways and genes/motifs essential for B lymphopoiesis. Hypo-C-DMRs tended to be proximal to genes with
elevated expression in contrast to the transcription silencing-mechanism imposed by hypermethylation. Hypo-
C-DMRs tended to be enriched in the regions of activating H4K4me1/2/3, H3K79me2, and H3K27ac histone
modifications. In comparison, the polycomb repressive complex 2 (PRC2) signature, marked by EZH2, SUZ12, CTCF
binding-sites, repressive H3K27me3 marks, and “repressed/poised promoter” states were associated with hyper-
C-DMRs. Most hypo-C-DMRs were found in introns (36 %), 3′ untranslated regions (29 %), and intergenic regions
(24 %). Many of these genic regions also overlapped with enhancers. The methylation of CpGs from 3′UTR exons
was found to have weak but positive correlation with gene expression. In contrast, methylation in the 5′UTR was
negatively correlated with expression. To better characterize the overlap between methylation and expression
changes, we identified correlation modules that associate with “apoptosis” and “leukocyte activation”.
Conclusions: Despite clinical heterogeneity in disease presentation, a number of methylation changes, both
hypo and hyper, appear to be common in B-CLL. Hypomethylation appears to play an active, targeted, and
complementary role in cancer progression, and it interplays with hypermethylation in a coordinated fashion in the
cancer process.
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Background
Loss of DNA methylation, also known as hypomethyla-
tion, in cancer cells relative to normal cells was one of
the first-described epigenetic changes in human cancers.
Hypomethylation has been detected at both a global
level and on a local scale [1] in cancer genomes. Many
cancer types have been reported to have global loss of
methylation like glioblastoma [2], ovarian epithelial car-
cinoma [3], prostate metastatic tumors [4], B cell
chronic lymphocytic leukemia [5, 6], hepatocellular car-
cinoma [7], cervical cancer [8], colon adenocarcinoma
[9], and Wilms’ tumor [10]. However, the biological sig-
nificance of DNA hypomethylation remains understud-
ied owning to its unclear role in carcinogenesis, in
contrast to hypermethylation, which is commonly
viewed as a transcription silencing mechanism [11, 12].
Yet, hypomethylation of DNA, despite its unclear role,
has been linked to tumor progression [8, 13] in different
tumor types and in individual specimens [3, 14]. Also,
some experiments have indicated the importance of in-
duced DNA hypomethylation in oncogenesis by using
DNA methylation inhibitors in vivo and in vitro [15, 16].
However, the role of hypomethylation is not clearly
understood. Hence, it is critical to analyze hypomethyla-
tion data in depth to achieve a better understanding of
its biological roles in carcinogenesis.
DNA hypomethylation in cancer is often seen in satel-
lite DNAs, Arthrobacter luteus (ALU) repeats, and long
interspersed nuclear elements (LINEs) [17, 18], etc.
These DNA repeats comprise approximately half of the
genome. Hence, DNA hypomethylation is generally con-
sidered a global phenomenon not suitable for use as a
biomarker. One advantage of the global hypomethylation
phenomenon (as it pertains to its genome composition)
is that it is often considered a technique to balance focal
and conserved hypermethylation in the promoter re-
gions of key genes. Also, it is believed that these hypo-
methylated genomic regions are randomly spread over
the genome, mostly in repetitive regions whose func-
tions, if any, are unclear. Again, this reported disadvan-
tage might actually be an advantage due to recent
findings indicating that ALU elements can act as en-
hancers [19], which further emphasizes the need for de-
fining the role of hypomethylation in cancers.
As part of our study of hypomethylation patterns, we
used B cell chronic lymphocytic leukemia (B-CLL) as an
example case. This B-CLL cancer type has a predomin-
ant global hypomethylation as its characteristic feature
[5, 6], and it is the most common form of blood cancer.
It is a clinically heterogeneous disease, with some pa-
tients experiencing rapid disease progression and others
living for decades without requiring treatment [20]. Al-
though a number of cellular and molecular prognostic
markers, i.e., surface markers ZAP70 and CD38,
cytogenetic abnormalities, and IGHV mutational status
[21–23], have been identified to help classify CLL into
molecular and clinical subgroups and to predict their
course of progression, they do not provide clear insight
into the underlying biology necessary to develop better
targeted and more effective treatments.
In addition to various molecular and genetic changes,
several genome-wide DNA methylation studies have
identified many aberrantly methylated genes in CLL
samples [24]. Initially, DNA hypermethylation in CLL
patients was found to affect 4.8 % of CpG islands on
average [25]. Furthermore, hypermethylation in the pro-
moters of tumor suppressor genes such as DAPK1 [26],
SFRP1 [27], and ID4 [28] genes involved in apoptosis,
cell cycle regulators p16 and p15 [29], and prognostic
markers ZAP70 [21] and TWIST2 [30] were identified.
DNA methylation changes were also found to be associ-
ated with disease progression in the Eμ-TCL1 transgenic
mouse model of CLL [28]. In addition to hypermethyla-
tion, hypomethylation of proto-oncogenes has also been
observed particularly in liver tumors and leukemia such
as the c-fos, c-myc, ras, Erb-A1 [31], and the bcl-2 gene
[32]. Along with this, many studies have indicated wide-
spread hypomethylation compared to instances of hyper-
methylation, particularly in the CLL cancer type.
However, a detailed account on the genome-wide hypo-
methylation pattern and its contributing role towards
cancer development has not been conducted for CLL.
Hence, it is clear that an in-depth methylation analysis
focusing more on hypomethylation can be very helpful
to unveil the underlying mechanism regulating the
disease.
Here, we studied the genome-wide DNA methylation
pattern in CLL and investigated whether hypomethyla-
tion is also consistent at some locations like hyperme-
thylation across multiple CLL patients. We also
investigated the biological role of consistent hypomethy-
lation towards tumor initiation and progression; and
finally, we compared instances of consistent hypomethy-
lation to that of consistent hypermethylation. We char-
acterized the epigenetic context of hyper- and
hypomethylated regions in CLL and further investigated
association of hypomethylation with change in expres-
sion of the neighborhood genes along with their poten-
tial mechanism of influence.
Results
Methylation data analysis
In order to study genome-wide methylation changes in
the CLL genome, we computed differentially methylated
regions (DMRs) from genome-wide methylation data of
30 samples from publically available CLL samples in
GEO (http://www.ncbi.nlm.nih.gov/geo/). DMRs of size
1000 bp were obtained by comparing each patient
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sample against each control normal sample individually
using Fisher’s exact test. False discovery rate (FDR) was
used to correct for multiple testing errors with a q value
threshold of 0.01. Hence, three sets of DMRs were ob-
tained by comparing all 30 CLL samples against each of
the three control samples.
Entropy and permutation analysis
Having obtained a list of all hypo- and hyper-DMRs for
each CLL against each control sample, we first plotted
the distribution of the number of samples in which each
DMR (hypo and hyper) existed. Figure 1a shows that the
majority of hypo-DMRs are present in less than 50 % of
samples. Out of the DMRs present in 20 or more sam-
ples, hyper-DMRs outnumbered hypo-DMRs. This
showed that overall hypomethylated regions are less
conserved than hypermethylated regions across samples.
Next, in order to check randomness in contrast to
conservation of methylation change in each 1000 bp re-
gion across all CLL samples, methylation entropies were
calculated using a probability distribution of methylation
changes for each region. Figure 1b shows this opposite
pattern of entropy and average methylation change. This
plot shows that a high percentage methylation of spe-
cific regions is more consistent across all patients;
however, as the average methylation goes down, their
conservation tends to fluctuate, thereby leading to an
increase in entropy (Fig. 1b). After comparing these
methylation entropies for each region against the
average methylation change across 30 CLL samples,
we observed a negative correlation (Pearson correl-
ation = −0.22, p value <0.05) in each of the 3-control
sample tests.
Identification of consistent differentially methylated regions
(C-DMRs)
In order to obtain consistent DMRs, a binomial test
was used to check the significance of each DMR with
the probability of being hypo/hypermethylated in 25
or more CLL samples (q value <0.01). Hence, three
lists of significant DMRs were obtained for each con-
trol sample. Next, 658 hypo- and 982 hypermethy-
lated regions that were found common in all three
lists and referred to as C-DMRs (see Tables S1–S4 in
Additional file 1 and Additional file 2 for lists and
details).
To further check the statistical significance of our lists
of hypo- and hyper-C-DMRs, we performed two permu-
tation tests, one by permuting samples and the other by
permuting methylation values for 1000 bp regions (see
Methods in Additional file 1 for more details). The sam-
ple permutation test helped in detecting whether we ob-
served hyper/hypo-C-DMR patterns by chance if there
was no difference among cancer vs. normal samples. On
the other hand, the methylated region permutation test
detected whether hyper/hypo-C-DMR pattern can occur
by chance if there is no difference between regions. In
both permutation tests, all of our obtained C-DMRs had
q values <0.05, showing the statistical significance of
hyper- and hypo-C-DMRs in cancer samples against
normal and non-DMRs.
Differences in positional genomic location analysis of
hyper- and hypo-C-DMRs
By checking the genomic-location distribution of C-
DMRs, we found that a higher number of hyper-C-
DMRs mapped to promoters (64 %) and 5′UTRs (43 %)
as compared to hypo-C-DMRs (14 % for promoters and
12 % for 5′UTR) and genomic background regions
(30 % for promoters and 29 % for 5′UTRs). A higher
percentage of promoter and 5′UTR hypermethylation
confirmed their role in interfering with transcription
factor binding (Fig. 2a, b). However, hypo-C-DMRs out-
numbered both hyper-C-DMRs and background gen-
omic regions for 3′UTRs (29 % in hypo-C-DMRs, 8 % in
hyper-C-DMRs, and 7 % in background) and introns
(36 % in hypo-C-DMRs, 4 % in hyper-C-DMRs, and
15 % in background). There were also more hypo-C-
DMRs (24 %) in the intergenic regions than hyper-C-
DMRs (18 %), but comparable with genomic background
regions (26 %). CpG sites from hypo- and hyper-C-
DMRs were also checked against “weak/strong enhancer
regions” chromatin states as defined by chromHMM
[33] and were found coming mostly from intronic and
intergenic regions on a genome. (Figure S6 in Additional
file 1). Strong enhancers were overlapped more by hypo-
C-DMRs in comparison to hyper-C-DMRs. Genes over-
lapping with hypomethylated strong enhancers were
ELN, GTF2I, KLC1, MIF4GD, MIR6821, MOB2, PTBP1,
RGS3, SH3BGRL3, TBC1D14, TCIRG1, and VASH2.
Across each sample data, we found 25–30 % of all
DMRs as hypomethylated, and only 10–15 % hyper-
methylated, as shown in Figure S1 in Additional file 1.
However, they were not targeted for any specific
chromosomal region (Figure S2 in Additional file 1).
Also, only 100 hypo-C-DMRs (15.2 %) co-localized with
CpG islands, while 955 out of 982 hyper-C-DMRs
(97.2 %) co-localized with CpG islands. Hypo-C-DMRs
were mostly present in regions outside CpG islands and
shores (Fig. 2c). Next, Fig. 2d shows that almost half of
hypo-C-DMRs (46 %) were present on non-repeat re-
gions along with ones mapped on the repeat regions.
Overall, hypo-C-DMRs were found more in 3′UTR,
intronic, and intergenic regions, mostly outside CpG
islands and overlapping both repeat and non-repeat
regions over enhancers. Additional file 3 lists the
genes with genic-regions overlapped by these C-
DMRs.
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Fig. 1 Overall representation of methylation. a Distribution of hyper/hypo-DMRs (tiles) over number of samples. This illustration shows that a
higher proportion of hypo-DMRs (compared to hyper-DMRs) are consistent in small subsets of samples. It also shows the presence of few hypo-
DMRs present in all 30 samples. b Relationship between average methylation difference across all CLL patients against control samples (SC1, SC2,
and SC4_1) and methylation entropy per 1000 bp region
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Enrichment of KEGG pathways, GO annotations and
phenotypes
For our obtained lists of hypo- and hyper-C-DMRs, we
performed enrichment analysis of genes overlapped by
C-DMRs (Additional file 3) for gene ontology (GO) [34]
categories and KEGG [35] pathways. The most signifi-
cantly enriched KEGG pathways in hypo-C-DMRs were
“B cell receptor (BCR) signaling pathway” (adjusted p
value (p.adj) = 2.21E-02), “p53 signaling pathway”
(p.adj = 3.69E-02), and “pathways in cancer” (p.adj =
3.69E-02), along with a few other signaling pathways
and pathways involved in cancer. In contrast, hyper-
C-DMRs were not enriched for any leukemia-related
pathway such as BCR signaling. Hyper-C-DMRs were
enriched for “neuroactive ligand-receptor interaction”
(p.adj = 7.29E-05) and for the “calcium-signaling path-
way” (p.adj = 9.86E-03) (Fig. 3). See Additional file 4
for complete enrichment results.
Among the GO annotations, the most important and
significantly enriched biological processes for hypo-C-
DMRs were “negative regulation of transcription” (p.adj =
4.28E-02), “chromatin modification” (p.adj = 3.92E-02),
Fig. 2 Distributions of C-DMRs. a, b Over different genic parts. c Over CpG islands. d Over genomic repeats and non-repeat regions
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“regulation of signaling” (p.adj = 3.92E-02), “histone
methylation” (p.adj = 3.92E-02); “positive regulation of his-
tone H3-K9 methylation" (p.adj = 4.29E-02), “protein
alkylation” (p.adj = 4.28E-02), “programmed cell death”
(p.adj = 4.30E-02), “negative regulation of cell prolifera-
tion” (p.adj = 4.40E-02), and “negative regulation of
Fig. 3 GO annotation and KEGG pathway enrichment for C-DMRs
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leukocyte differentiation” (p.adj = 3.04E-02), “leukocyte ac-
tivation” (p.adj = 4.28E-02), and “cell morphogenesis in-
volved in differentiation” (p.adj = 4.29E-02). On the other
hand, hyper-C-DMRs were enriched for processes which
are antagonistic to the processes enriched in hypo-C-
DMRs. Hyper-C-DMRs were enriched for processes like
“positive regulation of transcription” (p.adj = 4.81E-12)
and “positive regulation of cell differentiation” (p.adj =
1.99E-07), “positive regulation cell proliferation” (p.adj =
4.75E-06), “regulation of signaling” (p.adj = 3.53E-05) with
more processes related to “cell-fate commitment” (p.adj =
6.09E-13), “cell morphogenesis involved in differentiation”
(p.adj = 7.69E-08), and similar processes like “protein and
cell localization” (p.adj = 4.77E-06). Also, hypo-C-DMRs
were enriched for “H3K9 methylation” but hyper for “H3-
K27 methylation.”
Molecular functions (Fig. 3) showed a strong enrichment
for binding functions like “protein binding” (like integrin,
p.adj = 1.92E-02), “SH3 domain binding” (p.adj = 1.92E-02),
“p53 binding” (p.adj = 1.92E-02), “histone-arginine N-
methyltransferase activity” (p.adj = 2.20E-02), “tumor necro-
sis factor-activated receptor activity” (p.adj = 3.20E-02),
GTPase regulator activity (p.adj = 3.20E-02), and “transcrip-
tion factor binding” (p.adj = 3.40E-02) in hypo-C-DMRs. In
comparison, hyper-C-DMRs were specifically highly enriched
for “sequence-specific DNA binding” (p.adj = 5.49E-32), tran-
scription factor (or regulator, p.adj = 3.86E-25), and trans-
membrane transporter activity (p.adj = 6.58E-03), along with
also metal/ion (calcium, p.adj = 6.72E-07) and “enhancer
binding” (p.adj = 5.47E-05). In summary, both C-DMR
types (hypo and hyper) affected similar processes but
in different directions, with hypomethylation focusing
on transcription and leukocyte activation and hyperme-
thylation focusing on transcription suppression through
transcription factors and cell-fate commitment.
We did not observe any differences in enriched pheno-
types between hypo- and hyper-C-DMRs. Specific associa-
tions with the hematopoietic system, homeostasis/
metabolism, mortality/aging, immune system, and growth/
size phenotype were enriched in both types of C-DMRs,
except embryogenesis (or related terms like differentiation),
which was specific to hypermethylation. Genes falling
under each enriched top attribute are listed in Additional
file 5. These results suggest the importance of both hypo-
and hyper-C-DMRs in CLL, and emphasize the functional
significance of hypo-C-DMRs.
Enrichment of TFBS, histone modifications, and chromatin
states
Next, in order to identify epigenomic signatures associ-
ated with both C-DMRs, we systematically tested for en-
richment in transcription factor binding sites (TFBSs),
histone modification marks, and chromatin states pro-
vided by ENCODE project [36].
TFBS enrichment analysis identified EZH2 as strongly
associated with hyper-C-DMRs (p.adj = 1.70E-23), in
contrast to hypo-C-DMRs (p.adj = 4.27E-05, Fig. 4a). On
the contrary, EBF1, POL2, CHD2, WHIP, and TBLR1
were strongly associated with hypo-C-DMRs (p.adj =
2.53E-37, 1.06E-30, 2.17E-22, 6.024E-22, and 5.78E-19,
respectively), in contrast to hyper-C-DMRs (p.adj = 1.65E-
09 and 3.50E-07) (Fig. 4). Other than these, the HAIB data-
set in ENCODE showed additional B lymphopoiesis-
related enriched TFBS like RUNX3 (p.adj = 3.58E-31),
TCF3 (p.adj = 4.04E-14), PU.1 (p.adj = 7.42E-11), and PAX5
(p.adj = 7.43E-11). Both hyper- and hypo-C-DMRs were
enriched in ZNF143, CTCF, MAZ, and MXI1 TFBSs
(Fig. 4a). These findings were confirmed by using TFBS
data from all cell lines provided by the ENCODE project
(Figure S3 (a), S4 in Additional file 1 and Additional file 6).
Among histone modification marks, we found
H3K27me3 to be highly enriched in hyper-C-DMRs
(Fig. 4b, p.adj = 2.31E-40). On the contrary, hypo-C-
DMRs were strongly enriched in H3K4me1 (p.adj =
1.11E-54), H3K27ac (p.adj = 1.22E-38), and H3K79me2
(p.adj = 1.44E-34) histone modification marks (Fig. 4b).
Both C-DMRs were enriched in H3K4me2, H3K4me3,
and H2AZ histone modification marks (Fig. 4a). The
specificity of the H3K27me3 mark for hyper-C-DMRs
was confirmed by using histone modification data from
all cell lines provided by the ENCODE project (Figure
S3 (b) in Additional file 1 and Additional file 6).
Furthermore, hyper-C-DMRs were significantly enriched
for homeobox, E2F and TATAbox/promoter motifs, and
hypo-C-DMRS for ETS, IRF4, EGR, ZFX, RUNX1, PU.1,
Pax5, BATF, Erra, and bZIP motifs (Table S5 in Additional
file 1). All motifs enriched for hypo-C-DMR have been
shown to contribute to cell proliferation, B cell develop-
ment and pathogenesis of lymphomas [37–39].
Using chromatin state annotations from multiple cell lines
(Figure S3 (c) in Additional file 1 and Additional file 6), we
found hyper-C-DMRs to be enriched in “repressed”
(p.adj = 5.63E-182) and “poised promoters” (p.adj =
1.24E-69) chromatin states (Fig. 4c). In contrast, hypo-C-
DMRs were consistently enriched in both “strong/weak
enhancers” (p.adj = 6.73E-36 for both) and “weak tran-
scription” (p.adj = 2.73E-24). Both C-DMRs were similarly
enriched in “weak promoters” (p.adj = 1.70E-19 and 2.93E-
15 for hyper- and hypo-C-DMRs, respectively). These re-
sults suggest that distant enhancer regions tend to be
hypomethylated in cancer whereas regions associated with
repressed or poised transcription are hypermethylated.
Also, 17,811 hyper- and 15,599 hypo-differentially
methylated regions (DMRs) were obtained from pooled
CLL and control sample comparison (Table S2 in
Additional file 1). Each of these region lists exhaustively
included all hyper- and hypo-C-DMRs, respectively.
KEGG and GO annotation enrichment analysis of
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pooled sample DMRs also showed a strong enrichment
of similar terms (Additional files 1 and 4). Results from
pooled sample analysis show that C-DMRs are more
specific and significant subset of DMRs that are consist-
ently present in all samples.
Expression data analysis
Expression profiles in relation with methylation
Next, we looked at the association between gene expression
changes and methylation differences. For this, expression
values of all transcripts from 19 matching CLL samples
were divided into four expression quartiles and referred to
as lowest to highest expression groups. Methylation profiles
for genes in each of these quartiles were then extracted for
comparison. Figure 5a shows a significant reduction of
methylation at gene boundaries for all expression quartile
groups. At the peripheral region, methylation in the highest
expression genes is reduced the most. Towards the center,
methylation of CpGs and expression has an inverse rela-
tionship, with the lowest expression genes having the lowest
percent methylation. Overall, average methylation for whole
gene regions for all genes had a negative correlation (Pear-
son correlation = −0.07; p value = 3.1E-09) with expression.
Next, we looked for expression (transcript FPKM
values) and methylation (for overlapped CpG sites) rela-
tionship in exons and introns individually (Fig. 5d, e).
We observed that among exons (Fig. 5d), transcripts in
the lowest expression quartile had the highest and most
distinct methylation pattern. Overall, all exons combined
from transcripts in all expression quartiles had a nega-
tive correlation (corr = −0.13; p value <2.2E-16). For
introns (Fig. 5e), this relationship appeared to be oppos-
ite with the highest expression quartile transcripts show-
ing the highest methylation but almost no correlation
Fig. 4 Enrichment of C-DMRs in the regulatory regions. The ENCODE genome annotation datasets for Gm12878 lymphoblastoid cell line from
Broad and Stanford/Yale/USC/Harvard were used for transcription factor and Histone enrichment analyses (a, b). Broad datasets were used for
chromatin states enrichment (c). See Figures S3, S4 in Additional file 1 for the results for all cell lines. The vertical axis shows –log10-transformed
enrichment p values, FDR corrected. Left/right parts of the bar-plots show top 10 most significant enrichments for hyper/hypo-C-DMRs, respectively.
a Transcription factor binding sites enrichment. b Histone modification sites enrichment. c Chromatin states enrichment
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Fig. 5 Association between DNA methylation and expression in CLL samples. a Local regression showing methylation levels of whole genes
stratified by expression quartiles in CLL samples. b Local regression showing methylation levels within 5′ and 3′UTRs for different transcripts
stratified by expression quartiles. c Methylation levels within exons and introns for transcripts in different expression quartiles. d Methylation levels
at exon boundary in different expression quartiles. e Methylation levels at intron boundary in different expression quartiles
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(corr = −0.02; p value = 6.2E-2). Also, we identified a very
clear distinction in methylation patterns from different ex-
pression quartiles in exons specifically from 5'UTRs
(Fig. 5b). Overall, 5'UTRs had a negative correlation be-
tween methylation and expression (corr = −0.2; p value
<2.2E-16). Conversely, exons from 3'UTRs had the opposite
methylation pattern (Fig. 5c). 3'UTR exons from the highest
expression quartile genes had the highest methylation
(Fig. 5d, Figure S8 in Additional file 1) and overall, they had
weak but positive correlation (corr = 0.1; p value = 2.4E-3).
In summary, we observed different methylation effects on
expression for different genic regions, particularly within
exons from 5'UTR and 3'UTR that related to methylation
changes at widespread genomic locations in CLL.
Correlation module analysis
In order to further investigate the role of 3'UTR methy-
lation change on expression, we used both expression
and methylation data to construct co-expression and co-
differential methylation network modules, respectively.
These modules were generated using the weighted gene
correlation network analysis (WGCNA) framework [40].
For this, we selected 1780 transcripts from 19 matching
CLL samples, from which both expression and average
3'UTR methylation data were available.
WGCNA identified 21 co-expression modules with
sizes ranging from 41 to 181 transcripts from the ex-
pression data and 17 co-differential methylation modules
with sizes ranging from 37 to 284 transcripts from the
methylation data (average of all CpGs within 3'UTRs).
Methylation values of transcripts in each CLL sample
were compared against methylation of transcripts from
one common control sample, individually. Differential
methylation values for all transcripts in all CLL samples
were thus obtained. Correlation network modules in
each dataset were obtained using hierarchical clustering
of pairwise gene correlation structures using WGCNA.
WGCNA does not use gene ontology information but
clusters the interconnected genes defined as branches of a
hierarchical cluster tree. Hence, modules are initially la-
beled by arbitrary integers and then coded by colors for
each dataset. Since clustering for module generation has
no gene annotation or functional information, functional
interpretation for each module in each dataset was further
obtained by conducting a GO enrichment analysis. GO en-
richment analyses revealed unique and significant enrich-
ment of various GO terms, providing evidence of a
functional role for each module as a whole (Additional
file 7; Tables S2, S3, S8, and S9 in Additional file 1). Over-
all, different biological processes for different modules im-
plied biological significance of clustering transcripts in
separate modules in both expression and methylation data.
Next, to investigate the relationship between expres-
sion and methylation modules, these modules were
matched by pairwise comparison of each methylation
module to each expression module using two methods.
First, they were compared to measure a statistically sig-
nificant overlap of genes in each pair. Second, we used
network-based statistics to assess whether the density
and connectivity patterns of genes were also preserved
in a two-paired set of modules with significant gene
overlaps. The second method generated a composite
statistic value, i.e., Zsummary, using a permutation test to
measure the strength of methylation module and expres-
sion module preservation. Also, knowing the Zsummary
statistic bias towards a module with a large size, a rank-
based statistic medianRank was used in the second
method to measure their relative preservation irrespective
of module size. The medianRank is the statistic calculated
from observed preservation values and does not conduct
any permutation test against background gene modules.
From network preservation tests, we found that ex-
pression and differential methylation modules in general
exhibited relatively few overlapping genes (Additional
file 7) although some of the overlaps were statistically
significant. The most significant overlaps (p.adj < 0.05)
were observed between large co-expression modules and
co-differential methylation modules, enriched for same
GO terms (Table 1 and Additional file 7; Table S4 in
Additional file 1). Figure 6a reports the number of com-
mon genes resulting from pairwise module overlap analysis.
The statistical significance of each pair as shown by a color
scale was computed to see if the numbers of common
genes were obtained according to an iterative pattern and
not by chance. WGCNA arbitrarily color-code modules for
visual identification, so all color-module associations de-
scribed here do not have any additional meaning outside of
this specific analysis. The most significant overlap as shown
in Fig. 6a was for “turquoise” color-coded expression mod-
ule with “magenta,” “yellow”, and “midnight blue” methyla-
tion module. The turquoise expression module also had the
highest Zsummary (Zsummary = 28) and median rank from
network-based statistic method (Fig. 6b). GO enrichment
analysis of the turquoise expression module showed enrich-
ment of “TNFR,” “cell adhesion,” “leukocyte proliferation,”
and “apoptosis/cell death.” All the overlapping methylation
modules which were color-coded in magenta (enriched for
“EGF” p.adj = 1.60E-02), yellow (enriched for “focal adhe-
sion and kinases”), midnight blue (enriched for “cofactor
and ion binding”) were enriched for growth factor and
regulation of “Ras protein signal transduction,” “kinase ac-
tivity,” and “ion binding.” Hence, we see that the most sig-
nificantly overlapping and preserved modules in CLL
samples were the ones involved in cancer development.
This also indicates the regulatory role of 3′UTR methyla-
tion on expression change in cancer.
Also, “green,” “pink,” “blue,” “black,” and “grey60”
color-coded expression modules were the other top
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modules showing a strong preservation (Zsummary >10)
and low median rank (Fig. 6b). All these four modules
were again enriched for “zinc ion binding,” “regulation
of transcription,” and “apoptosis”. They overlapped with
“light cyan,” “midnight blue,” “black,” and “turquoise”
methylation modules. Biological processes like “cell div-
ision,” “chromosome partitioning/cytoskeleton,” and
“GTPase regulator activity” were enriched in both
“grey60” (second least rank = 5, Zsummary = 13) expres-
sion module along with its overlapping red methylation
module (Additional file 7). An additional network analysis
was carried out using expression and average methylation
of whole genes (not just 3′UTRs) that are non-coding (i.e.,
transcripts that do not encode a protein product) along
with 3′UTR methylation. Results from this analysis can be
accessed in Additional file 7. This non-coding RNA analysis
also gave results similar to the 3′UTRs, including overlap
of modules enriched for similar cancer-related terms.
Hence, we see that significantly preserved expression and
methylation modules were enriched for similar cancer-
related biological processes like leukocyte proliferation,
apoptosis, signal transduction, and cell-cycle regulation.
Our observation from network preservation of expression
and 3′UTR methylation change provides clues for a better
understanding of the contribution made by the regulatory
role imposed by 3′UTR methylation overexpression.
Next, a correlation analysis between methylation and
expression modules was conducted using module eigen-
gene (aka eigennode) that is intuitively understood as a
weighted average of the variable profiles in a module. Al-
though the composition of co-expression and co-
differential methylation modules can vary, we observed
multiple strong Pearson correlations between many ex-
pression and methylation module eigengenes as shown
in Fig. 7, and Tables S6 and S12 in Additional file 7. For
example, in our non-coding gene analysis, eigengenes of
“red” methylation module was highly negatively correlated
(corr = −0.97, p value = 5.75E-12) to a “brown” expression
module. The red methylation module was enriched for
“regulation of cell cycle” and “intracellular signal cas-
cade” and “brown” expression module for apoptosis
and leukocyte proliferation as per GO analysis, show-
casing complimentary functional annotations involved
in cancer regulation (Tables S8 and S9 in Additional
file 7). Similarly, eigengenes of the blue methylation
module were significantly and positively correlated
(corr = 0.95, p value = 1.22E-09) to the “dark red” ex-
pression module, both of which were enriched for
“protein localization” or “intracellular transport”
(Figure S6 in Additional file 7). Also, we saw both
significantly positive and negative correlations in 3′
UTR methylation to expression modules and occa-
sionally for the same module. For example, red ex-
pression module (enriched for “kinases and nucleotide
binding”) was negatively correlated with “green”
(enriched for “nucleotide binding” and “positive regulation
of apoptosis”) and positively correlated with “midnight
blue” and “tan” (both enriched for “nucleotide binding”)
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Brown (197) Light green (49) 12 (5.48E-03) 9.8 9 Apoptosis/cell death UEVLD,UNC13B,DTNB,BANP,IRF7,CCNL2,
INTS9,FNTA,RBM19,DNASE1,GRB7
Midnightblue (45) Turquoise (181) 10 (1.24E-02) 28 6 Ion binding ABLIM2,ACE,COMMD1,ELFN2,GLT1D1,
HAUS7,TOM1
Turquoise (284) Midnight blue (55) 15 (2.11E-02) 12 2 Nucleotide binding ADCY9,AGTRAP,BSDC1,INO80E,MCHR1,
MTHFSD,NADK,P4HB,PDE8A,POR,RAB3A,
RPS19BP1,SMUG1,SOX12,STX8
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Fig. 6 (See legend on next page.)
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3′UTR methylation modules. All together within the
3′UTR methylation correlations, we observed a ma-
jority of positive correlated modules of lower signifi-
cance compared to negative correlated modules of
high significance. Correlation in different directions
can be assumed to be due to location of methylation
differences within exons or introns, as we saw in our
previous analysis and the direction of methylation
change. Overall, we observed significant correlations
in modules enriched for cancer-related terms, giving
evidence of the role of methylation change in 3′UTRs
towards tumorigenesis.
(See figure on previous page.)
Fig. 6 Module preservation. a Table showing gene overlap between each pair of methylation and expression modules. Each row of the table
corresponds to one methylation module (labeled by color as well as text), and each column corresponds to one expression module. Numbers in
the table indicate gene counts in the intersection of the corresponding modules. Coloring of the table encodes − log(p), with p being the Fisher’s
exact test p value for the overlap of the two modules. The stronger the red color, the more significant the overlap is between a methylation
module for 3′UTR and an expression module. b Plot showing statistical analysis results for module preservation test to check preservation of 3′
UTR methylation modules against expression modules based on the density and connectivity patterns of genes in each module. The left panel
shows the medianRank of the observed preservation statics and the right panel shows the distribution of Zsummary statistics obtained from a
permutation analysis for each methylation module. A module with a lower median rank tends to exhibit stronger observed preservation statistics
than a module with a higher median rank. The Zsummary statistic of a given module summarizes the evidence that the network connections of
the module are more significantly preserved than those of random set of genes of equal size. The significance thresholds for Zsummary are
Zsummary < 2 implies no evidence that the module is preserved, 2 < Zsummary < 10 implies weak to moderate evidence, and Zsummary > 10 implies
strong evidence for module preservation between co-expression module and 3′UTR methylation module
Fig. 7 Pairwise correlation between each methylation module to each expression module. Plot showing correlation between eigengenes of each 3′
UTR methylation and expression modules. X-axis shows all 17 differential methylation modules, and Y-axis shows the module eigengene correlation
value for each of the 21 different color-coded dots representing 21 expression modules. Statistical significance of each correlation was calculated and
represented by dot size for each corresponding methylation module
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Interplay between hypo- and hypermethylation
Also, while describing the importance of hypomethyla-
tion in CLL, we described the overall interplay among
hyper/hypomethylation and gene expression change.
Figure 8 shows both methylation and expression change
information together for key cancer and cell cycle-
regulating genes. Genes are marked as hypo- or hyper-
methylated if any of the respective C-DMRs overlap on
them. As observed from all our enrichment analyses,
Fig. 8 shows that growth and proliferation is dominated
by hypomethylation whereas hypermethylation blocks
cell-cycle exiting and differentiation. We can see many
instances where opposite methylation changes target
genes in the same process but still coordinate with each
other towards cancer development. Both hyper- and hy-
pomethylation changes were found within the same net-
work based on functional role or direction of target gene
in the network. For instance, although, all genes involved
in cell growth and proliferation are targeted by hypome-
thylation and have activated transcription, PF4—which is
known to be involved in inhibition of hematopoiesis and
PTEN, is hypermethylated. PF4 negatively regulates the
PI3K-AKT/PKB signaling pathway and acts as a tumor-
suppressor and hence, hypermethylated and repressed.
Similarly, in order to drive the cell cycle forward to pro-
gress through subsequent phases of cell cycle and escape
cell-cycle exit, Fig. 8 shows much complementary coord-
ination of opposite methylation changes. We can see
how the FOS gene, which is involved in cell-cycle exit is
repressed in CLL samples but CyclinD1 and its other
genes, which are required for G1-S phase transition in
cell-cycle progression are hypomethylated. Hypomethy-
lation of genes involved in G1-S transition, thereby en-
ables uncontrolled cell division. Also, all genes involved
in inhibiting apoptosis are hypomethylated leading to
their transcription activation. These examples show how
hypo- and hypermethylation coordinate with each other
to impose a double negative effect towards the same goal
of cancer development in CLL.
Discussion
Role of hypomethylation in cell-cycle regulation, histone
modification, and transcription activation in CLL
Hypermethylation at the promoter region of tumor sup-
pressors and their subsequent silencing is a well-studied
mechanism of tumorigenesis. In contrast, hypomethyla-
tion, potentially leading to upregulation of oncogenes, is
not fully understood. Also, genic hypomethylation is
often considered as a random and non-consistent
process due to a particularly predominant de-
methylation process in mature B cells in CLL samples.
In this study, we showed that consistent hypomethylated
Fig. 8 Coordination of hypo- and hypermethylation in cell-cycle regulation in cancer. Plot showing coordination between direction of methylation
and expression change in cancer regulation. Each gene is colored showing their methylation change along with up or down arrow showing how their
expression changes. Genes that are not marked by color or arrow shows no corresponding data recorded
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regions (referred to here as hypo-C-DMRs) account for
a significant pattern of methylation changes in CLL with
a distinctive pattern of gene expression and regulatory
associations.
In particular, we observed that both hypo- and hyper-
C-DMRs were enriched for similar biological processes
but in an opposite direction. For example, hyper-C-
DMRs were enriched for “positive regulation of cell dif-
ferentiation”, but hypo-C-DMRs were enriched for
“negative regulation of cell differentiation.” We also ob-
served a significant enrichment of BCR signaling associ-
ated with hypo-C-DMRs. This further strengthens the
importance of hypomethylation in CLL since BCR is a
central pathogenic mechanism in B cell malignancies, in-
cluding CLL [41]. In addition, GO annotations relate to
transcription regulation, chromatin modification, apop-
tosis, cell proliferation, leukocyte differentiation, and sig-
nal transduction were enriched for hypo-C-DMR, which
also defines their functional role in cancer development.
Also, the most significantly enriched TFBS for hypo-
C-DMRs was EBF1, which is a transcription factor that
is critical for both B lymphopoiesis and B cell function
[42]. EBF1, in collaboration with a hierarchy of partner
proteins, including E2A, Runx1, and Pax5 (also enriched
in motif analysis) activates the B cell transcriptome and
represses programs of alternate hematopoietic lineages.
DNA binding by EBF1 has also been linked to changes
in epigenetic marks on their target genes. Binding of
EBF1 and other factors including E2A have also been
correlated with H3K4me1 at target genes, which is also
the most enriched histone modification mark in our ana-
lysis. H3K4me1 is in fact known to facilitate additional
epigenetic modifications necessary for transcription [43].
RUNX3, TCF3, PU.1, and PAX5 are also key transcrip-
tion factors in B lymphopoiesis and cell proliferation.
Other TFBS enriched for hypo-C-DMRs were POL2,
CHD2, WHIP, and TBLR1. CHD2 is a DNA-binding heli-
case that specifically binds to the promoter of target
genes, leading to chromatin remodeling and promoting
their expression [44]. WHIP is a protein that binds to
DNA polymerase delta and increases the initiation fre-
quency of DNA polymerase delta-mediated DNA syn-
thesis [45]. TBLR1 is a key regulator of different
properties of the BCL-3 [46] that acts as an oncogenic
protein through multiple mechanisms that include the
induction of cyclin D1 expression and also inhibits cell
apoptosis through induction of the E3 ligase of p53,
MDM2 [47, 48]. Among other enriched histone modifi-
cations, H3K79 di-methylation is known for regulating
the initiation of DNA replication [49], and H3K36me3 is
found in actively transcribed gene bodies of genes in-
volved in G1/S transition in a cell cycle [50]. Presence
of hypo-C-DMR overlapping enhancers and weak pro-
moters further emphasize their role in activation of
transcription. Overall, both enriched TFBS and
histone modifications are known to relate to B lym-
phopoiesis, transcription activation, and cancer
development.
In contrast to hypo-C-DMRs, hyper-C-DMRs, which
are known to regulate the expression silencing mechan-
ism, were implicated by the enrichment of EZH2. EZH2
contains a histone methyltransferase SET domain that
methylates histone tails on gene promoters to repress
their transcription initiation, and this domain is an
important component of the polycomb repressive
complex 2 (PRC2). The PRC2 protein EZH2 is also
known to preferentially methylate Lysine 27 on histone
3 (H3K27) [51] and also H3K9 under certain conditions.
H3K27me3 and H3K9me3 were both enriched for
hyper-LSDMRs in our analysis as well. H3K4me3,
H3K9me3, and H3K27me3 co-localizes with most poly-
comb target proteins like SUZ12, CTBP2, and EZH2-
binding sites enriched in hyper-C-DMRs (Additional file
1; Figure S5). Several other studies [51, 52] have re-
ported DNA methylation and tumor suppressors in can-
cers marked with polycomb proteins enriched with
EZH2 and H3K27me3. This study also elucidates the
known mechanism of hyper-C-DMR in gene silencing
and promoting cancer development. Further, enrichment
of repressor chromatin region for hyper-C-DMRs con-
firms their role in silencing the expression of target
genes.
Our motif enrichment analysis showed hypermethyla-
tion enriched for motifs like homeobox and TATAbox,
which are usually present in promoter regions and thus
silence many key genes. In contrast, hypomethylation
was enriched in motifs of transcription activator binding
genes, such as ETS [38], ZFX [37], cMYC [39] (Table 1),
which are again involved in cell growth, apoptosis, and
metabolism, processes necessary for tumor progression.
Enriched transcription factor motifs like Ikaros (IKZF)
and PU.1 govern B cell lineage priming, which involves
changes in histone modifications and chromatin struc-
ture of genes encoding molecules important for the es-
tablishment of a B cell program [53]. Other significant
classes of motifs enriched in hypo-C-DMRs were motifs
containing ETS domain in genes like Elk1 and Fli and
RHD domain in genes like NFAT and NFkB-p65. These
genes are downstream nuclear targets of Ras-MAP kin-
ase signaling and are also known as oncogenic transcrip-
tion activators, specific to [54] cell survival and
proliferation.
Methylation pattern in exons, introns, and 3′UTRs
In addition to evidence of transcription activation, we
observed that hypomethylation in CLL mostly targets
intronic, intergenic, and 3′UTR regions. Regarding
the relationship between methylation and expression
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change with respect to genic locations, we found
negative correlation for methylation in exons and
whole transcript expression within 30 CLL samples.
But, this correlation within exons was inconsistent in
UTRs. Exons in 5′UTRs seem to act more like pro-
moters, but exons in 3′UTRs had the opposite effect
on expression. Hence, these findings suggest that in
contrast to a gene expression-inhibiting role of in-
creasing methylation associated with 5′UTR exons,
methylation in 3′UTR exons is in fact required in the
normal transcription process.
Regulation of expression by 3′UTR methylation pattern
Our co-expression and co-methylation network ana-
lysis revealed that both transcriptome and methylome
can be organized into modules. Genes in co-
methylation and co-expression modules were found
highly enriched for specific gene ontology categories,
underscoring their functional importance. Many 3′
UTR modules associated with methylation changes
were found to have moderate to strong preservation
with expression modules. Also, the most preserved
module had functional annotations related to signal-
ing and growth and proliferation. Hence, preserved 3′
UTR methylation and expression modules revealed
the ability of 3′UTR methylation to dictate their ex-
pression. The regulatory behavior of methylation
change could, therefore, be detected—not only in 5′
UTR, promoters, and gene bodies—but also in 3′
UTRs in CLL. Also, significantly correlated 3′UTR
methylation and expression modules were enriched
for biologically important pathways involved in signal-
ing cascade, apoptosis, and cell proliferation. These
results provide a fine-grained look at the interaction
among 3′UTR co-methylation and co-expression
modules altered in CLL.
In summary, we report that hypomethylation of DNA
appears to facilitate the aberrant expression of proto-
oncogenes/oncogenes, potentially stimulating cell prolif-
eration in CLL. We observed that apart from global hy-
pomethylation of repeat sequences, there also exists site-
specific hypomethylation of certain genes and genic re-
gions, especially in genes linked with signaling pathways
(e.g., BCR, LYN RAB8A, NFKBIB), chromatin modifica-
tions (e.g., CHD2, CHD3, SMARCB1), cell growth and
development (e.g., EBF1, EGR1, EGFR, ERBB2, MYC),
apoptosis inhibition (e.g., BCL2, TRAF1), and promoting
cell proliferation (e.g., CCND1, LYN, BCL3). We ob-
served 3′UTRs to possess a high percentage of hypo-
DMRs consistent in the majority of our test samples.
We report genes with 3′UTR consistent hypomethyla-
tion in CLL like LIF and PIM3. Along with that, we also
report genes with consistent hypermethylation in CLL in
3′UTRs like HMX2 and other genic regions. We also
observed that methylation changes at 3′UTR had signifi-
cant correlation with expression along with overlapping
network modules in both datasets. Our findings, thus,
suggest that hypomethylation in different genic regions
might exhibit a significant deleterious effect on gene ex-
pression that results in malignant transformation and/or
tumor progression.
Conclusions
We observed that hypomethylated regions were less
consistent over the genome among different samples, in
contrast to hypermethylation loci. However, some hypo-
methylated regions were highly consistent in most of the
samples, and their functional analysis revealed their po-
tential biological significance in CLL.
We observed hypomethylation at many genes con-
taining key TFBS involved in cell growth and devel-
opment, histone remodeling, apoptosis, and cellular
proliferation. We found hypomethylation in many
key signaling regulators consistent in majority of
samples, which do not appear to be random events
or a non-specific part of global hypomethylation. In
addition, this study contributes to our understanding
about the relationship between methylation and ex-
pression levels in CLL samples. Results from pos-
itional analyses for genic location indicate that the
conventional model of methylation regulating ex-
pression in an antagonistic manner is most com-
mon. However, we also uncovered an interesting and
conflicting relationship between methylation and ex-
pression for methylation occurring in exons of 3′
UTRs. Specifically, we found evidence of a loss of
DNA methylation that not only causes genomic in-
stability but also potentially activates many genes
mainly in signaling pathways like BCR in CLL.
Finally, we showed that 3′UTR methylome and
transcriptome are organized into biologically mean-
ingful modules with significant correlations and
strong-to-moderate preservation of their density and
connections between two datasets. The preserved
modules were also found as functionally related in-




Publicly available reduced representation bisulfite se-
quencing (RRBS) methylation for 30 CLL and three
control samples were obtained from the GEO website
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GS
E66121). Control samples were CD19+ B cells isolated
from peripheral blood of normal controls. Human
genome annotation data from the UCSC genome
browser (hg19 genome assembly), such as Refseq and
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UCSC genes, CpG islands, Vista Enhancers, ENCODE
Transcription Factor ChIP-Seq, and RepeatMasker
Tracks, were used to annotate differentially methyl-
ated regions of interest. For genes with multiple iso-
forms, the longest one was used as the reference.
Promoter regions were selected from −2 kb upstream
to the transcription start site of each gene.
Read mapping and % methylation
The bisulfite-treated sequencing reads in DNA methyla-
tion data for CD19+ B cells were mapped to bisulfite-
converted human genome using Bismark [55] (using
Bowtie). Bismark was used also to obtain the genome-
wide cytosine methylation calls at a base resolution in
the CpG context. Additional file 8 provides read map-
ping count tables for each sample.
Sequencing reads from RNA-seq experiments were
mapped using Bowtie with known ENSEMBL tran-
scripts as gene models. After mapping, FPKM values
for each gene/transcript were calculated by Cufflinks
[56] and differentially expressed (DE) genes were de-
fined by abs(ln(fold-change)) > 1.5. FDR-corrected p <
0.05 for all DE genes were calculated by Cuffdiff [57].
Next, the over enriched GO categories were obtained
based on a .05 FDR cutoff using the GO-seq R
package.
DMR calculation
Considering the high correlation between methylation of
adjacent CpGs, the methylation information obtained
from RRBS data was summarized on 1000 bp tiling win-
dows (step-size 1000 bp) with minimum 3 CpGs and
minimum 10 reads mapped on each CpG using the R
package, methylKit [58]. For DMR calculation, pairwise
comparison of 1000 bp tiles in each of the 30 tumor
samples against each control normal sample was per-
formed using Fisher’s exact test. From each such test,
differential methylation values were obtained only for
the regions that were common between CLL and control
sample. Thirty such tests were conducted for each con-
trol sample. Next, in order to ensure comparable statis-
tics, only those regions that had differential values from
each of the 30 tests were used. This gave us 41,421 com-
mon regions obtained from the first control sample
comparison tests. Similarly, 39,327 and 41,359 regions
were obtained from each of the other two control
samples.
Entropy calculation
Also, the methylation entropy across all CLL samples
was calculated in order to see probability distribution of
methylation changes for each 1000 bp region across all
samples. Entropy for each sample was computed as
follows:
The methylation vector mr of region r across N sam-
ples was defined as,
mr¼mr;1;mr;2;…;mr;5;…;mr;N
where mr,s represents the methylation level in sample s.
The sum of methylation levels of region r in samples
(∑S = 1
N mr,s) was treated as a total methylation value. The
ratio of methylation level of region in sample relative
to the total value was defined as the relative methyla-
tion probability, ps/r =mr,s/∑S = 1
N mr,s. The original







Enrichment analysis of genes overlapped by C-DMRs for
GO categories and KEGG pathways was performed
using GOStats R package [59]. Gene set enrichment for
gene symbols overlapping hypo-C-DMRs was also per-
formed using GeneDecks [60] to highlight shared de-
scriptors between pairs of genes based on annotations
within the GeneCards compendium of human genes.
The epigenomic enrichment analysis of C-DMRs was
performed using Genome Runner [61]. Briefly, genomic
coordinates of hyper- and hypo-C-DMRs were collected
and tested for co-localization with three groups of gen-
ome annotation datasets: (1) chromatin state segmenta-
tion by HMM from ENCODE/Broad, (2) histone
modifications by ChIP-seq from ENCODE/Broad Insti-
tute and ENCODE/Stanford/Yale/USC/Harvard, and (3)
experimentally validated transcription factor binding
sites from ENCODE/Broad Institute and ENCODE/
Stanford/Yale/USC/Harvard. Genomic regions annotated
by the ENCODE with any functional/regulatory informa-
tion (~80 % of the whole genome) were used as a “back-
ground” to estimate co-localizations that can occur by
chance. p values were calculated using Chi-square test
and corrected for multiple testing using FDR.
Motif analysis was also carried out using Homer [62]
software after retrieving sequences around each DMR
CpG along with those around non-DMR CpGs randomly
chosen as a background.
Expression in relation to methylation analysis
To associate gene expression changes with methylation
differences, all CpG average methylation values were
paired with the average expression of transcripts they
overlap in all CLL samples. Estimated expression profiles
of all transcripts were divided into four expression quar-
tiles and referred to as lowest to highest expression
groups within all transcripts. The positional enrichment
analysis for each gene region was performed using
Homer, and R scripts were used to calculate and plot
smoothened density estimates. Locfit library was used
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for fitting local regression, likelihood models, and related
smoothing procedures.
Correlation of whole transcript expression to methyla-
tion of CpGs within each specific gene region was calcu-
lated by using the Pearson correlation coefficient. For
correlation calculation average methylation of CpGs
(across all CLL samples) in a specific gene region and
average expression of the whole transcript corresponding
to these CpGs were used.
Correlation module analysis
From 19 matching CLL samples from both methylation
and expression data, we obtained differential methyla-
tion and differential expression (FPKM) for 3′UTRs of
1780 transcripts. For this, whole transcript expression
and average methylation for all CpGs in each of its 3′
UTRs were used. Differential expression and 3′UTR
methylation for each transcript was then computed by
comparing each CLL sample individually against one
common control sample.
We then used differential expression and methylation
value matrices to identify co-expression and co-
differential methylation network modules through the
WGCNA R package (see Additional file 7 for more de-
tails), individually on each dataset. WGCNA computes
networks by calculating each gene-to-gene pairwise cor-
relation and interconnection strength by checking num-
ber of shared neighbors. It then finally generates
modules using hierarchical clustering. Tables S1 and S2
in Additional file 7 provide a list of 10 top hub genes
(genes with most significant module membership) in
each module, and Additional file 9 consists of module
membership values for all genes in each expression and
methylation module.
After constructing modules in each dataset, we
checked to see if any of the modules in one dataset were
preserved in any of the modules from the other data set
using two approaches: cross tabulation and network-
based statistics. In cross tabulation, overlaps of the con-
stituent genes in each pair of modules from the two data
sets were calculated and Fisher’s exact test was used to
assign a p value to each overlap. In the second method,
we used network module preservation statistics (NP) de-
scribed in and implemented in [63] the WGCNA R
package. The NP method not only assesses the signifi-
cant overlap of genes, but also whether the density and
connectivity patterns of modules defined in a reference
data set are preserved in a test data set. We considered
expression data as reference data and methylation data
as test data. This NP statistic test calculates statistic
values based on density and connectivity preservation
within reference and test modules. From calculated stat-
istic values, the NP test in the WGCNA package module
was used to obtain two values, (1) the median rank,
which is the rank for the average of the observed preser-
vation static values and (2) a composite module preser-
vation statistic referred to as Zsummary using a
permutation test. Thus, we reported a Zsummary for each
expression module in the methylation modules.
Also, since WGCNA groups together highly corre-
lated variables to generate modules, we summarized
the variable profiles in each module to a single repre-
sentative, i.e., the module eigengene. The module
eigengene, which is defined as the first principal
component of the standardized matrix containing var-
iables in the module was used to calculate the correl-
ation between expression and methylation within
non-coding genes and 3′UTRs.
Also, since non-coding genes do not translate and do
not undergo post-transcription changes (i.e., stripping 3′
UTRs) with no defined UTR or a gene body region (or
in other words—whole portion can be identified as
UTR), we also conducted the same network analysis by
including non-coding genes.
Additional files
Additional file 1: Additional Figures, Tables and Methods. This is a
“docx” file, which includes various additional figures, tables and
methods that are referred in the main text supporting this research.
(DOCX 3304 kb)
Additional file 2: List of C-DMRs. This is an “xls” file providing coordinates
for hyper- and hypo-C-DMRs common across all control tests in separate
excel sheets, respectively. (XLS 117 kb)
Additional file 3: Gene lists for C-DMRs. This is an “xls” file providing
a list of genes overlapped by common hyper and hypo-C-DMRs in
separate excel sheets, respectively. It also consists of excel sheets for
genes overlapping different gene regions for hypo- and hyper-C-
DMRs, respectively. (XLS 56 kb)
Additional file 4: KEGG and GO enrichment analysis results. This is an
“xls” format file that provides enrichment test results from GOStats
package for KEGG pathways and GO biological processes for both hyper-
and hypo-C-DMRs and DMRs from pooled sample analysis in separate
excel sheets, respectively. (XLS 916 kb)
Additional file 5: Phenotype enrichment analysis results. This is an “xls”
format file that provides enrichment results for phenotype with different
phenotype descriptors, their enrichment p values along with their count
and names of their corresponding genes sharing that descriptor for both
hypo- and hyper-C-DMRs in separate excel sheet, respectively. (XLS 81 kb)
Additional file 6: ENCODE enrichment results. This is an “xls” file that
provides the ENCODE epi-genomic mark enrichment analysis results from
Gm12878 cell line with the name and the description of the datasets,
enrichment p values that are adjusted for multiple testing using FDR, for
hypo/hyper-C-DMRs in separate excel sheets, respectively, along with the
name of the regulatory mark. It also consists of enrichment analysis
results from all ENCODE cell lines for each regulatory mark in hypo- and
hyper-C-DMRs. (XLS 117 kb)
Additional file 7: WGCNA. This is a “docx” file that describes correlation
modules in details, together with the step-by-step description of WGCNA
analysis. WGCNA description includes data cleaning and preprocessing,
adjacency topological overlap matrix construction, module detection,
calculation of various module measures, and description of preservation
statistics methods used. It includes tables and figures for both 3′UTR
methylation and non-coding gene data, and their relation with
expression of genes analysis. (DOCX 1555 kb)
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Additional file 8: Read mapping details. This file provides the mapping
statistics for all the samples in both RRBS and RNA-seq datasets. Table S1
lists the number of RRBS reads obtained, their % that is uniquely mapped
on human genome (hg19) along with total number of CpGs analyzed
from each sample. Table S2 lists the number of RNA-seq reads obtained
and their % that is uniquely mapped on human genome (hg19) for each
sample. (DOCX 124 kb)
Additional file 9: Gene module membership. This is an “xls” file that
provides the matrix for transcript’s module membership or eigengene-
based connectivity measure of each transcript for each methylation and
expression module for 3′UTRs in separate excel sheet, respectively.
(XLS 1395 kb)
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